Today, Caduceus Capital Partners, LLC is proud to spotlight New Day Therapeutics, a member of Caduceus LAUNCH’s fall cohort.
“The Caduceus leaders’ deep digital health expertise truly sets the LAUNCH program apart from other accelerators and investors. It’s both inspiring and enlightening to collaborate with fellow cohort members who share a dedicated focus on healthcare.” Steve Barns, Co-founder and CEO, New Day Therapeutics
New Day Therapeutics supports people who suffer from PTSD, anxiety and depression by enrolling patients in an AI-guided program of daily, low dose oral ketamine with monitoring adherence and results via an app. By integrating continuous AI monitoring, crisis intervention, and peer counseling, New Day delivers a responsive, evidence-based, and compassionate approach to care—powered by technology and grounded in human connection. Learn more at https://newdaythera.com/.
Applications for the Caduceus LAUNCH spring 2026 cohort open December 1. Visit www.caduceus.vc/launch to learn more.